LUND, Sweden, Dec. 10, 2020 /PRNewswire/ -- Alligator
Bioscience (Nasdaq Stockholm: ATORX) today announced the
completion of a novel proprietary human synthetic antibody library
in Fab (Fragment antigen-binding) format - ALLIGATOR-FAB™. The
design of the library and antibody diversity has been optimized to
ensure the development of highly functional antibodies with
excellent developability properties.
The ALLIGATOR-FAB library is built on multiple antibody
backbones with optimal drug development properties to further
increase the structural diversity of generated antibodies. The
ALLIGATOR-FAB library has been shown to generate pools of highly
diverse and functional antibody variants.
"ALLIGATOR-FAB is a great addition to our technology platform
and perfectly complements our well-established
ALLIGATOR-GOLD® library as well as the bispecific format
RUBY™. With the two human antibody libraries at hand, Alligator has
the capacity to generate therapeutic mono- and bispecific
antibodies against virtually any target", said Per Norlén, CEO of
Alligator Bioscience.
ALLIGATOR-FAB has been key in the generation of the latest drug
candidate in Neo-X-Prime, the novel immuno-oncology concept
recently launched by Alligator.
For further information, please contact:
Cecilia Hofvander, Director Investor
Relations & Communications
Phone +46 46 540 82 06
E-mail: cecilia.hofvander@alligatorbioscience.com
The information was submitted for publication, through the
agency of the contact person set out above, at 08:30 a.m. CET
on December 10, 2020.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's pipeline includes the two key assets ATOR-1017 and
mitazalimab. Furthermore, there are two partnered assets:
ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and
AC101 in clinical development by Shanghai Henlius Biotech Inc. In
addition, the company has developed a novel concept for more
patient-specific immunotherapy: Neo-X-Prime. Alligator's shares are
listed on Nasdaq Stockholm (ATORX). The Company is headquartered in
Lund, Sweden. For more
information, please visit www.alligatorbioscience.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-launches-alligator-fab----a-novel-human-antibody-library,c3252051
The following files are available for download:
https://mb.cision.com/Main/12681/3252051/1346472.pdf
|
Alligator Bioscience
launches ALLIGATOR-FABâ„¢ â€" a novel human antibody
library
|